IL17A and uveitis: Secukinumab (CosentyxR) is a fully human monoclonal antibody against IL-17A and isadministered subcutaneously.[87]Three phase-III trials examined the efficacy of Secukinumab in patients withBD-associated uveitis, active NIU, and quiescent NIU.[87] None of these studies showed a statisticallysignificant difference in uveitis recurrence between Secukinumab and placebo.